The inhalation cdmo market size has grown strongly in recent years. It will grow from $2.2 billion in 2025 to $2.35 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to rising prevalence of asthma and copd, increasing demand for inhalation therapies, growth of biologics and specialized drug formulations, advancements in formulation technologies, increasing outsourcing by pharmaceutical companies.
The inhalation cdmo market size is expected to see strong growth in the next few years. It will grow to $3.03 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to expansion of digital and smart inhalers, growth in personalized medicine and precision therapy, increased investment in inhalation cdmo infrastructure, rising adoption of advanced manufacturing technologies, increasing collaborations between biotech firms and cdmos. Major trends in the forecast period include personalized inhalation therapy development, advanced formulation and drug delivery techniques, regulatory compliance and quality assurance enhancements, contract manufacturing expansion for small and medium-sized firms, integration of smart inhalers and digital health monitoring.
The growing prevalence of respiratory disorders is expected to drive the expansion of the inhalation CDMO market in the coming years. Respiratory disorders encompass a range of medical conditions that impact the respiratory system, including the organs and structures responsible for breathing. Inhalation CDMOs support the development and manufacturing of therapies for respiratory conditions by leveraging their expertise in pulmonary drug formulation and delivery, along with specialized infrastructure and resources that help pharmaceutical companies advance innovative inhalation treatments. For instance, in December 2023, data from the National Library of Medicine, a US-based medical library, indicated that the global number of chronic obstructive pulmonary disease (COPD) cases among individuals aged 25 and older is expected to increase by 23% by 2050, reaching nearly 600 million. Therefore, the rising prevalence of respiratory disorders is contributing to the growth of the inhalation CDMO market.
Major companies operating in the inhalation CDMO sector are increasingly pursuing strategic partnerships to enhance specialized drug development and delivery capabilities. A strategic partnership refers to a long-term, mutually advantageous collaboration between two or more organizations working together to achieve common objectives. For instance, in May 2023, Hovione, a Portugal-based contract development and manufacturing organization, entered into a partnership with H&T Presspart, a UK-based manufacturer of high-precision metal and plastic components for the pharmaceutical industry, to develop Presspart’s Sunrise capsule-based dry powder inhaler platform. This collaboration is centered on advancing new technologies capable of delivering higher drug doses and improving the effectiveness of pulmonary drug delivery.
In January 2025, Molex Inc., a US-based medical technology company, acquired Vectura Group Ltd. for an undisclosed consideration. Through this acquisition, Molex seeks to substantially broaden its presence in inhalation drug delivery and development by incorporating Vectura’s extensive expertise in formulation science, device engineering, and combination product manufacturing. Vectura Group is a UK-based medical company specializing in the development and manufacture of inhalation therapies.
Major companies operating in the inhalation cdmo market are Baxter’s BioPharma Solutions, Lonza Group AG, Catalent Inc., Siegfried Holding AG, Recipharm AB, Stevanato Group SpA, CordenPharma, Nemera, Hovione FarmaCiencia SA, Vectura Group Ltd., CARBOGEN AMCIS, Kindeva Drug Delivery Ltd., Frontage Laboratories Inc, Sanner GmbH, H&T Presspart Ltd., Astech Projects Ltd, Cliantha Research, Copley Scientific, Cambrex Corporation, AptarGroup Inc.
North America was the largest region in the inhalation contract development and manufacturing organization (CDMO) market in 2025. The regions covered in the inhalation cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inhalation cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have posed challenges for the inhalation CDMO market by increasing the cost of imported raw materials, excipients, and specialized manufacturing equipment. This has impacted production efficiency and timelines, particularly affecting segments like DPIs and MDIs in regions such as Asia-Pacific, Europe, and North America, which are major manufacturing and sourcing hubs. While costs have risen, some companies are leveraging local sourcing and domestic manufacturing to mitigate these impacts, creating opportunities for regional market growth and enhanced supply chain resilience.
The inhalation cdmo market research report is one of a series of new reports that provides inhalation cdmo market statistics, including inhalation cdmo industry global market size, regional shares, competitors with a inhalation cdmo market share, detailed inhalation cdmo market segments, market trends and opportunities, and any further data you may need to thrive in the inhalation cdmo industry. This inhalation cdmo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
An inhalation contract development and manufacturing organization (CDMO) is a specialized entity that offers end-to-end services to pharmaceutical and biotechnology companies for the development and production of inhalable therapies. These organizations provide a broad range of services specifically designed for inhalation products, including formulation development, analytical evaluation, process optimization, scale-up activities, and commercial-scale manufacturing.
The key product categories in the inhalation CDMO space include dry powder inhalers (DPIs), metered dose inhalers (MDIs), nebulizers, and soft mist inhalers. Dry powder inhalers (DPIs) are devices designed to deliver medications to the lungs as a dry powder. They are used to treat various disease indications such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, acute respiratory distress syndrome, and pulmonary fibrosis, and they are classified by technology, including manual inhalers (SMIs) and digital inhalers. The end users of these products include large pharmaceutical companies, small and medium-sized pharmaceutical companies, generic drug manufacturers, and others.
The inhalation contract development and manufacturing organization (CDMO) market includes revenues earned by providing services such as formulation development, analytical testing, device compatibility testing, process development and optimization, scale-up, and manufacturing. The market value includes the value of related goods sold by the service provider or included within the service offering. The inhalation contract development and manufacturing organization (CDMO) market also includes sales of metered-dose inhalers, dry powder inhalers, and inhalation suspension products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The inhalation cdmo market size is expected to see strong growth in the next few years. It will grow to $3.03 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to expansion of digital and smart inhalers, growth in personalized medicine and precision therapy, increased investment in inhalation cdmo infrastructure, rising adoption of advanced manufacturing technologies, increasing collaborations between biotech firms and cdmos. Major trends in the forecast period include personalized inhalation therapy development, advanced formulation and drug delivery techniques, regulatory compliance and quality assurance enhancements, contract manufacturing expansion for small and medium-sized firms, integration of smart inhalers and digital health monitoring.
The growing prevalence of respiratory disorders is expected to drive the expansion of the inhalation CDMO market in the coming years. Respiratory disorders encompass a range of medical conditions that impact the respiratory system, including the organs and structures responsible for breathing. Inhalation CDMOs support the development and manufacturing of therapies for respiratory conditions by leveraging their expertise in pulmonary drug formulation and delivery, along with specialized infrastructure and resources that help pharmaceutical companies advance innovative inhalation treatments. For instance, in December 2023, data from the National Library of Medicine, a US-based medical library, indicated that the global number of chronic obstructive pulmonary disease (COPD) cases among individuals aged 25 and older is expected to increase by 23% by 2050, reaching nearly 600 million. Therefore, the rising prevalence of respiratory disorders is contributing to the growth of the inhalation CDMO market.
Major companies operating in the inhalation CDMO sector are increasingly pursuing strategic partnerships to enhance specialized drug development and delivery capabilities. A strategic partnership refers to a long-term, mutually advantageous collaboration between two or more organizations working together to achieve common objectives. For instance, in May 2023, Hovione, a Portugal-based contract development and manufacturing organization, entered into a partnership with H&T Presspart, a UK-based manufacturer of high-precision metal and plastic components for the pharmaceutical industry, to develop Presspart’s Sunrise capsule-based dry powder inhaler platform. This collaboration is centered on advancing new technologies capable of delivering higher drug doses and improving the effectiveness of pulmonary drug delivery.
In January 2025, Molex Inc., a US-based medical technology company, acquired Vectura Group Ltd. for an undisclosed consideration. Through this acquisition, Molex seeks to substantially broaden its presence in inhalation drug delivery and development by incorporating Vectura’s extensive expertise in formulation science, device engineering, and combination product manufacturing. Vectura Group is a UK-based medical company specializing in the development and manufacture of inhalation therapies.
Major companies operating in the inhalation cdmo market are Baxter’s BioPharma Solutions, Lonza Group AG, Catalent Inc., Siegfried Holding AG, Recipharm AB, Stevanato Group SpA, CordenPharma, Nemera, Hovione FarmaCiencia SA, Vectura Group Ltd., CARBOGEN AMCIS, Kindeva Drug Delivery Ltd., Frontage Laboratories Inc, Sanner GmbH, H&T Presspart Ltd., Astech Projects Ltd, Cliantha Research, Copley Scientific, Cambrex Corporation, AptarGroup Inc.
North America was the largest region in the inhalation contract development and manufacturing organization (CDMO) market in 2025. The regions covered in the inhalation cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inhalation cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have posed challenges for the inhalation CDMO market by increasing the cost of imported raw materials, excipients, and specialized manufacturing equipment. This has impacted production efficiency and timelines, particularly affecting segments like DPIs and MDIs in regions such as Asia-Pacific, Europe, and North America, which are major manufacturing and sourcing hubs. While costs have risen, some companies are leveraging local sourcing and domestic manufacturing to mitigate these impacts, creating opportunities for regional market growth and enhanced supply chain resilience.
The inhalation cdmo market research report is one of a series of new reports that provides inhalation cdmo market statistics, including inhalation cdmo industry global market size, regional shares, competitors with a inhalation cdmo market share, detailed inhalation cdmo market segments, market trends and opportunities, and any further data you may need to thrive in the inhalation cdmo industry. This inhalation cdmo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
An inhalation contract development and manufacturing organization (CDMO) is a specialized entity that offers end-to-end services to pharmaceutical and biotechnology companies for the development and production of inhalable therapies. These organizations provide a broad range of services specifically designed for inhalation products, including formulation development, analytical evaluation, process optimization, scale-up activities, and commercial-scale manufacturing.
The key product categories in the inhalation CDMO space include dry powder inhalers (DPIs), metered dose inhalers (MDIs), nebulizers, and soft mist inhalers. Dry powder inhalers (DPIs) are devices designed to deliver medications to the lungs as a dry powder. They are used to treat various disease indications such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, acute respiratory distress syndrome, and pulmonary fibrosis, and they are classified by technology, including manual inhalers (SMIs) and digital inhalers. The end users of these products include large pharmaceutical companies, small and medium-sized pharmaceutical companies, generic drug manufacturers, and others.
The inhalation contract development and manufacturing organization (CDMO) market includes revenues earned by providing services such as formulation development, analytical testing, device compatibility testing, process development and optimization, scale-up, and manufacturing. The market value includes the value of related goods sold by the service provider or included within the service offering. The inhalation contract development and manufacturing organization (CDMO) market also includes sales of metered-dose inhalers, dry powder inhalers, and inhalation suspension products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Inhalation CDMO Market Characteristics
3. Inhalation CDMO Market Supply Chain Analysis
4. Global Inhalation CDMO Market Trends and Strategies
5. Inhalation CDMO Market Analysis of End Use Industries
7. Global Inhalation CDMO Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Inhalation CDMO Total Addressable Market (TAM) Analysis for the Market
9. Inhalation CDMO Market Segmentation
10. Inhalation CDMO Market Regional and Country Analysis
11. Asia-Pacific Inhalation CDMO Market
12. China Inhalation CDMO Market
13. India Inhalation CDMO Market
14. Japan Inhalation CDMO Market
15. Australia Inhalation CDMO Market
16. Indonesia Inhalation CDMO Market
17. South Korea Inhalation CDMO Market
18. Taiwan Inhalation CDMO Market
19. South East Asia Inhalation CDMO Market
20. Western Europe Inhalation CDMO Market
21. UK Inhalation CDMO Market
22. Germany Inhalation CDMO Market
23. France Inhalation CDMO Market
24. Italy Inhalation CDMO Market
25. Spain Inhalation CDMO Market
26. Eastern Europe Inhalation CDMO Market
27. Russia Inhalation CDMO Market
28. North America Inhalation CDMO Market
29. USA Inhalation CDMO Market
30. Canada Inhalation CDMO Market
31. South America Inhalation CDMO Market
32. Brazil Inhalation CDMO Market
33. Middle East Inhalation CDMO Market
34. Africa Inhalation CDMO Market
36. Inhalation CDMO Market Competitive Landscape and Company Profiles
37. Inhalation CDMO Market Other Major and Innovative Companies
40. Inhalation CDMO Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Inhalation CDMO Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses inhalation cdmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for inhalation cdmo? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The inhalation cdmo market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Dry Powder Inhaler (DPIs); Metered Dose Inhaler (MDIs); Nebulizer; Soft Mist Inhaler2) By Disease Indication: Asthma; Chronic Obstructive Pulmonary Disease (COPD); Pulmonary Arterial Hypertension; Acute Respiratory Distress Syndrome; Pulmonary Fibrosis
3) By Technology: Manual Inhalers (SMI); Digital Inhalers
4) By End-User: Big Pharmaceutical Companies; Small and Medium-sized Pharmaceutical Companies; Generic Pharmaceutical Companies; Other End-Users
Subsegments:
1) By Dry Powder Inhaler (DPIs): Capsule-Based DPIs; Diskus-Style DPIs; Multi-Dose DPIs; Unit-Dose DPIs2) By Metered Dose Inhaler (MDIs): Pressurized MDIs (pMDIs); Breath-Actuated MDIs; Soft Mist MDIs
3) By Nebulizer: Jet Nebulizers; Ultrasonic Nebulizers; Mesh Nebulizers; Portable Nebulizers
4) By Soft Mist Inhaler: Respimat Inhalers; Other Soft Mist Inhalation Devices
Companies Mentioned: Baxter’s BioPharma Solutions; Lonza Group AG; Catalent Inc.; Siegfried Holding AG; Recipharm AB; Stevanato Group SpA; CordenPharma; Nemera; Hovione FarmaCiencia SA; Vectura Group Ltd.; CARBOGEN AMCIS; Kindeva Drug Delivery Ltd.; Frontage Laboratories Inc; Sanner GmbH; H&T Presspart Ltd.; Astech Projects Ltd; Cliantha Research; Copley Scientific; Cambrex Corporation; AptarGroup Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Inhalation CDMO market report include:- Baxter’s BioPharma Solutions
- Lonza Group AG
- Catalent Inc.
- Siegfried Holding AG
- Recipharm AB
- Stevanato Group SpA
- CordenPharma
- Nemera
- Hovione FarmaCiencia SA
- Vectura Group Ltd.
- CARBOGEN AMCIS
- Kindeva Drug Delivery Ltd.
- Frontage Laboratories Inc
- Sanner GmbH
- H&T Presspart Ltd.
- Astech Projects Ltd
- Cliantha Research
- Copley Scientific
- Cambrex Corporation
- AptarGroup Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.35 Billion |
| Forecasted Market Value ( USD | $ 3.03 Billion |
| Compound Annual Growth Rate | 6.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
